A retrospective cohort analysis carried out by a team of Hong Kong researchers found an association between low-dose aspirin and lung cancer-related mortality in patients with COPD. The study findings, published in PLOS Medicine, demonstrated that receiving treatment with aspirin vs no aspirin was associated with a 25 percent decreased risk for lung cancer. The investigators sourced the data from the Clinical Data Analysis Reporting System in Hong Kong and conducted inverse probability of treatment weighting to balance baseline covariates between aspirin vs non aspirin groups to reach the findings. The study also found a 26 percent reduction in lung cancer-related mortality for patients receiving treatment with aspirin.